Related references
Note: Only part of the references are listed.Cancer treatment and survivorship statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Current status of DILD in molecular targeted therapies
Yoshinobu Saito et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2012)
A Japanese Post-marketing Surveillance of Cetuximab (Erbitux) in Patients with Metastatic Colorectal Cancer
Megumi Ishiguro et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Post-marketing studies can make important contributions to medical knowledge
Martin C. Michel
BRITISH MEDICAL JOURNAL (2012)
Colorectal cancer molecular biology moves into clinical practice
Colin C. Pritchard et al.
GUT (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions
Muhammad Wasif Saif et al.
CLINICAL COLORECTAL CANCER (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature
Muhammad Wasif Saif et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
International Trends in Colorectal Cancer Incidence Rates
Melissa M. Center et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer
Kei Muro et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
Louis M. Weiner et al.
CLINICAL CANCER RESEARCH (2008)
Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer
Thomas H. Cartwright et al.
CLINICAL COLORECTAL CANCER (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
S. Siena et al.
BRITISH JOURNAL OF CANCER (2007)
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
Aya Jakobovits et al.
NATURE BIOTECHNOLOGY (2007)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER (2007)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
Panitumumab in colorectal cancer
Zev A. Wainberg et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study
Sabine Tejpar et al.
LANCET ONCOLOGY (2007)
Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: A case report
James Heun et al.
CLINICAL COLORECTAL CANCER (2007)
Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer
Eric Van Cutsem
ONCOLOGIST (2006)
Severe acute interstitial pneumonia and gefitinib
A Inoue et al.
LANCET (2003)
Share Paper
